{"product_id":"vvos-ansoff-analysis","title":"(VVOS) Vivos Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Vivos Therapeutics, Inc. Ansoff Matrix Analysis maps the company’s growth options—market penetration, market development, product development, and diversification—and explains how its products (oral appliance therapy for sleep-disordered breathing) fit each quadrant. The page contains a real preview\/sample of the analysis so you can judge style and substance; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. and Canada general-dentist channel deepening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics can deepen penetration by lifting adoption within its existing U.S. and Canada general-dentist base, not by changing the core Vivos System. The U.S. has about 200,000 dentists and Canada about 25,000, so even small gains in repeat use and new-office conversion can move revenue fast. Its licensed-medical-professional model supports this, since the same channel can drive more placements with lower incremental go-to-market cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult OSA and snoring case conversion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can expand adult OSA and snoring case conversion by pushing its current Vivos System into a huge unmet market: about 1 billion adults worldwide are estimated to have obstructive sleep apnea. The non-invasive, non-surgical, drug-free model helps dentists turn more screenings into treatment, lifting penetration in the installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivoScore screening-to-treatment funnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivoScore can widen Vivos Therapeutics, Inc.'s funnel by turning more screening leads into Vivos System therapy, especially in a U.S. OSA market where about 80% of moderate-to-severe cases remain undiagnosed. The program already pairs comprehensive screening with home sleep tests for adults and children, so it lowers friction from first contact to treatment. Better screening-to-treatment conversion should lift sales inside the current market without needing new categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDentofacial abnormality treatment emphasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. should frame the Vivos System more tightly for adults with dentofacial abnormalities, so the message stays aligned with its OSA and snoring focus and is easier for practitioners to adopt. Adult sleep apnea is common: about 30 million U.S. adults have it, and nearly 80% of moderate to severe cases remain undiagnosed, which supports a clearer entry point. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on adult dentofacial cases\u003c\/li\u003e\n\u003cli\u003eMatch OSA and snoring positioning\u003c\/li\u003e\n\u003cli\u003eReduce confusion for dentists\u003c\/li\u003e\n\u003cli\u003eUse the 30 million market signal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensed-professional education and activation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can grow faster by getting more use from the licensed dentists it already has, not just adding new ones. The direct lever is activation: in 2025, every extra practice using the multidisciplinary therapy model more often should raise patient starts without a big jump in fixed costs.\u003c\/p\u003e\n\u003cp\u003eGeneral dentists sit at the center of the channel, so education that shows how airway, sleep, and dental care work together can lift case flow. If even a small share of current providers moves from occasional use to routine use, market penetration improves with the same sales base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on current general dentists\u003c\/li\u003e\n\u003cli\u003eTeach the multidisciplinary care model\u003c\/li\u003e\n\u003cli\u003eRaise case frequency per provider\u003c\/li\u003e\n\u003cli\u003eUse activation as the main lever\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Can Grow Faster by Activating Its 225,000-Dentist Channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can drive market penetration by getting more use from its current U.S. and Canada dentist base and converting more of the estimated 30 million U.S. adults with sleep apnea. With about 80% of moderate-to-severe cases still undiagnosed, tighter screening, VivoScore, and routine provider activation can raise starts without changing the core Vivos System.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLever\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent channel\u003c\/td\u003e\n\u003ctd\u003e225,000 dentists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOSA gap\u003c\/td\u003e\n\u003ctd\u003e80% undiagnosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket pool\u003c\/td\u003e\n\u003ctd\u003e30M U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix view of Vivos Therapeutics, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Vivos Therapeutics Ansoff Matrix snapshot to quickly align growth strategy across existing and new markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary regulatory filings, clinical data, investor presentations, and peer-reviewed studies to validate Ansoff Matrix growth paths for Vivos Therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader licensed-provider reach beyond general dentists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics can extend the Vivos System beyond general dentists to sleep physicians, ENTs, and other licensed providers who treat sleep-disordered breathing. That is market development: the therapy stays the same, but the buyer channel widens. With about 30 million U.S. adults affected by obstructive sleep apnea, even modest provider adoption can open a much larger patient pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjacency into sleep-care referral networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics can win new sleep-care referral networks by partnering with practices that co-manage OSA and snoring patients, where demand for non-invasive options stays high. Its appliance-based model fits referrals from dentists, ENTs, and sleep clinics that want alternatives to drugs or surgery. That gives Vivos Therapeutics a low-friction way to place existing products into a broader care path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChildren and family screening expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can use VivoScore’s adult and child screening to tap family care pathways, not just adult-only sleep workflows. Pediatric obstructive sleep apnea affects about 1% to 6% of children, so the child-testing feature widens the addressable market without changing the core screening product. That makes the same tool useful for whole-family referrals and earlier capture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeographic expansion within North America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can drive market development by widening coverage across more local practice markets in the U.S. and Canada, rather than changing the product set. The play is reach, not reinvention: more orthodontists, dentists, and sleep-focused clinics in the same two-country base. In FY2025, this kind of geographic pull matters more than product launch risk because the company already has a North American channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand practice reach within U.S. and Canada.\u003c\/li\u003e\n\u003cli\u003eUse the same product line.\u003c\/li\u003e\n\u003cli\u003eTarget more local clinics, not new products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOSA and snoring awareness outside the core dental base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOSA and snoring awareness outside the core dental base can widen Vivos Therapeutics, Inc.’s addressable market, since the Vivos System already fits treatable sleep-disordered breathing demand. Nearly 1 billion adults worldwide are estimated to have obstructive sleep apnea, so even modest awareness gains can open new patient and practice channels beyond dental adopters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand into non-dental referral paths\u003c\/li\u003e\n\u003cli\u003eUse existing OSA and snoring positioning\u003c\/li\u003e\n\u003cli\u003eTarget awareness-driven demand pockets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Expands Reach Across Sleep Apnea Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. is pursuing market development by pushing the same Vivos System into more referral paths, especially sleep physicians, ENTs, and broader clinic networks. That fits a large base: about 30 million U.S. adults have obstructive sleep apnea, and nearly 1 billion adults worldwide are estimated to be affected. Child screening via VivoScore also widens access, since pediatric OSA affects about 1% to 6% of children.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket development lever\u003c\/th\u003e\n\u003cth\u003eRelevant number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. adult OSA pool\u003c\/td\u003e\n\u003ctd\u003eAbout 30 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal adult OSA pool\u003c\/td\u003e\n\u003ctd\u003eNearly 1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric OSA rate\u003c\/td\u003e\n\u003ctd\u003e1% to 6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eVivos Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. It covers Vivos Therapeutics’ market penetration, product development, market development, and diversification strategies with actionable insights. The full, editable report is available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos System therapy refinements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. should keep refining the Vivos System for adults with dentofacial abnormalities, obstructive sleep apnea, and snoring, since product development here means better therapy, not a new market. The priority is to preserve its non-invasive, non-surgical, drug-free profile while improving fit, comfort, and adherence.\u003c\/p\u003e\n\u003cp\u003eThat matters because sleep apnea affects about 39 million adults in the U.S., and snoring remains a large adjacent need. If Vivos can lift completion and satisfaction in this base, it can deepen repeat use without changing its core Ansoff path.\u003c\/p\u003e\n\u003cp\u003eNear-term refinements should focus on outcomes, ease of use, and clinical workflow, since those are the levers that can move adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivoScore Program expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivoScore expansion is a product development move that deepens Vivos Therapeutics, Inc.'s screening and home sleep test service as a complement to therapy. Since the program already serves adults and children, adding workflow features can widen use across more patient paths and strengthen the diagnostic-to-therapy funnel in a market where obstructive sleep apnea affects millions of people. That should support higher conversion from screening to treatment and more repeat clinical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated screening and treatment bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can bundle VivoScore with the Vivos System to create one care path from screening to treatment. That fits a market where obstructive sleep apnea affects about 25 million U.S. adults, so providers want fewer handoffs and faster starts. Product development should focus on one workflow, simpler ordering, and easier follow-up for clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePractice-support tools for licensed professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. should add practice-support tools that let dentists and other licensed providers screen, manage, and track patients inside the same platform. This is product development in the Ansoff Matrix because it deepens use of the current offer, while reducing workflow friction that can slow provider adoption. \u003c\/p\u003e\n\u003cp\u003eBy embedding patient intake, case tracking, and follow-up tools, Vivos Therapeutics, Inc. can make the service more useful at the point of care and increase repeat use. In a model that depends on provider adoption, simpler workflows can matter more than new features alone. \u003c\/p\u003e\n\u003cp\u003eKey focus: fewer clicks, clearer patient status, and better visibility across the treatment path. This supports stickier usage without changing the core market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScreen patients faster\u003c\/li\u003e\n\u003cli\u003eTrack cases in one place\u003c\/li\u003e\n\u003cli\u003eCut workflow friction\u003c\/li\u003e\n\u003cli\u003eLift platform adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChild-friendly workflow enhancements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can lift VivoScore adoption by tightening child screening and home sleep-test steps for pediatrics. Since children are already in scope, the upside is usability, faster clinic flow, and fewer setup errors, which can help more existing practices use the platform. Child-focused workflow fixes matter because pediatric sleep-disordered breathing is common and often missed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSimpler pediatric intake\u003c\/li\u003e\n\u003cli\u003eCleaner home-test setup\u003c\/li\u003e\n\u003cli\u003eBetter practice adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Focuses on Better Fit, Comfort, and Workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development for Vivos Therapeutics, Inc. means improving the Vivos System and VivoScore for existing adult and pediatric patients, not entering a new market. The focus is better fit, comfort, screening, and workflow so providers use the platform more often. With U.S. sleep apnea affecting about 39 million adults, even small gains in adherence and clinic flow can lift adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. adults with OSA\u003c\/td\u003e\n\u003ctd\u003e39 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFocus\u003c\/td\u003e\n\u003ctd\u003eFit, comfort, workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric airway-health solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can widen from adult OSA and snoring into pediatric airway-health solutions, and VivoScore already gives it a child entry point. Pediatric sleep-disordered breathing affects about 1% to 5% of children, so a child-focused line could tap a real unmet need. That would shift Vivos Therapeutics, Inc. beyond its adult-centered treatment base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital care coordination platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics can diversify by building a digital care coordination platform for screening, patient handoffs, and follow-up, adding a new product line next to its device and testing service. With obstructive sleep apnea affecting about 1 billion adults worldwide, this could widen reach across dental, medical, and telehealth providers. It also helps standardize care across geographies and keep patients in the workflow longer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjunct diagnostic services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can extend beyond screening and home sleep tests into adjunct diagnostic services, adding a new offer to its current sleep-care stack. With obstructive sleep apnea affecting about 1 billion adults worldwide, broader diagnostics can widen reach and catch more cases earlier.\u003c\/p\u003e\n\u003cp\u003eThat shift fits Ansoff Matrix diversification because it pairs a new service with a broader market, not just more of the same test. It can also lift per-patient revenue if Vivos bundles assessment, testing, and follow-up care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProvider training and implementation services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. can add a separate revenue stream by packaging provider training, onboarding, and practice-implementation services for licensed professionals. That supports adoption beyond the core treatment system, especially in new clinics and specialties. The shift fits Ansoff diversification because the company sells a new service layer to a wider provider base, not just a device.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eNew service stream\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFaster clinic onboarding\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBroader provider adoption\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational licensed-provider markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational licensed-provider markets would be a true Diversification move for Vivos Therapeutics, Inc. because the company is still centered in the U.S. and Canada, so entering Europe, Latin America, or Asia would add a new customer base and new regulatory paths. If Vivos Therapeutics, Inc. pairs local distribution, training, and support with its licensed-provider model, it can spread revenue risk beyond North America.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew geography, new demand pool\u003c\/li\u003e\n\u003cli\u003eNeeds localized offers and support\u003c\/li\u003e\n\u003cli\u003eMoves from market development to diversification\u003c\/li\u003e\n\u003cli\u003eCan reduce North America concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Expands Beyond OSA Into Pediatric and Digital Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification for Vivos Therapeutics, Inc. means moving beyond adult OSA devices into new offers like pediatric airway care, digital care coordination, and provider services. That fits Ansoff because it adds new products and new users; OSA affects about 1 billion adults, while pediatric sleep-disordered breathing affects 1% to 5% of children.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric line\u003c\/td\u003e\n\u003ctd\u003e1% to 5% children\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital platform\u003c\/td\u003e\n\u003ctd\u003eNew service layer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider training\u003c\/td\u003e\n\u003ctd\u003eNew revenue stream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235154600201,"sku":"vvos-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vvos-ansoff-matrix.webp?v=1785735720","url":"https:\/\/dcfanalyst.com\/products\/vvos-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}